We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
Read MoreHide Full Article
QIAGEN N.V.’s (QGEN - Free Report) first-quarter 2025 adjusted earnings per share (EPS) were 55 cents, and 56 cents at constant exchange rate (CER). The bottom line increased 17% from the year-ago level. Additionally, it surpassed the Zacks Consensus Estimate by 10%.
The adjustment excludes the impact of certain non-recurring items, such as business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.
On a GAAP basis, EPS in the first quarter was 41 cents compared with 36 cents in the year-ago period.
Following the announcement, QGEN stock rose 1.1% yesterday.
QGEN’s Q1 Revenues
Net sales in the quarter were $483.5 million, up 5.4% from the year-ago figure (up 7% at CER). The top line beat the Zacks Consensus Estimate by 4.8%. (See the Zacks Earnings Calendar to stay ahead of market-making news.)
QGEN’s Q1 Revenue Breakdown
QIAGEN reports through product groups, namely Sample technologies, Diagnostic solutions, PCR / Nucleic acid amplification, Genomics / NGS and Other.
Sample technologies revenues plunged 3% on a reported basis (down 1% at CER) to $150 million. Our model projected $148 million for this segment.
Diagnostic solutions revenues rose 9% on a reported basis (11% at CER) to $187 million. Our model projected $183.7 million for this segment.
Within this, on a CER basis, QuantiFERON revenues were up 16% and QIAstat-Dx revenues surged 37%. Sales from NeuMoDx fell 36% at CER, while Other sales dropped 9% from the year-earlier level.
PCR/Nucleic acid amplification revenues increased 13% on a reported basis (up 14% at CER) to $76 million. Our model projected $66.6 million for this segment.
Genomics / NGS revenues totaled $53 million, down 3% year over year on a reported basis and 2% at CER. Our model projected $55 million for this segment.
Other revenues amounted to $18 million, up 57% year over year on a reported basis (up 64% at CER). Our model projected $10.7 million for this segment.
QIAGEN’s Operational Update
In the first quarter, the company’s cost of sales (excluding the amortization of acquisition-related intangibles) fell 6.3%. The adjusted gross profit rose 4.9% year over year to $322.2 million. Meanwhile, the adjusted gross margin contracted 29 basis points (bps) to 66.6%.
Sales and marketing expenses fell 4.3% year over year to $106.3 million. R&D expenses of $43.8 million were down 14.7% year over year. G&A expenses rose 14.6% year over year to $31.6 million.
Adjusted operating income (excluding items like acquisition-related intangible amortization, restructuring, integration and others) increased 20% year over year to $140.4 million. The adjusted operating margin expanded 354 bps to 29%.
QGEN’s Financial Update
QIAGEN exited the first quarter of 2025 with cash, cash equivalents and short-term investments of $963.4 million compared with $1.20 billion at the end of the fourth quarter of 2024.
The long-term debt (net of the current portion) was $1.35 billion at the end of the first quarter of 2025 compared with $1.34 billion at the end of the fourth quarter of 2024.
The net cash provided by operating activities at the end of the first quarter of 2025 was $139.7 million compared with $133.1 million in the year-ago period.
QIAGEN Reaffirms Outlook for 2025, Sets Q2 View
For 2025, net sales are expected to increase about 4% CER (about +5% CER core sales growth). The Zacks Consensus Estimate for revenues is pegged at $2.02 billion.
The adjusted EPS is expected to be $2.35 at CER (up from the previous outlook of $2.28 at CER). The Zacks Consensus Estimate is pegged at $2.27.
For the second quarter, the company estimates net sales to rise about 5% at CER (about 5% at CER in the core business) from $496 million in the prior-year period. The Zacks Consensus Estimate is currently pinned at $505.9 million.
The adjusted EPS is expected to be at least 60 cents at CER compared with 55 cents in the second quarter of 2024. The Zacks Consensus Estimate is pegged at 56 cents.
Our Take on QGEN
QIAGEN ended the first quarter of 2025 with better-than-expected results, wherein both earnings and revenues surpassed their respective estimates. The company’s performance reflect a resilient portfolio, with a substantial portion of sales coming from highly recurring revenues and a continued emphasis on delivering solid profitable growth in a challenging environment.
Diagnostic solutions registered the highest growth, driven by strong demand for QuantiFERON and QIAstat-Dx. PCR/Nucleic acid amplification technologies also posted solid growth, supported by the continued adoption of the QIAcuity digital PCR system. Consumables and related revenues grew while instrument sales were flat year over year, reflecting ongoing cautious capital spending trends among customers. Additionally, the expansion of operating margin in the quarter is encouraging.
QIAGEN remains focused on delivering on its 2025 outlook, paving the way for achieving its 2028 goal. However, rising costs and declining gross margins do not bode well.
QGEN’s Zacks Rank and Other Key Picks
QIAGEN currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks from the broader medical space are AngioDynamics (ANGO - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Boston Scientific (BSX - Free Report) .
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a loss of 13 cents. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 70.9%.
Integer Holdings, sporting a Zacks Rank #1 at present, posted a first-quarter 2025 adjusted EPS of $1.31, which outpaced the Zacks Consensus Estimate by 3.1%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%.
ITGR has an estimated long-term earnings growth rate of 20.8% compared with the industry’s 14.3%. The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 2.8%.
Boston Scientific, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 2.3%.
BSX has an estimated 2025 earnings growth rate of 15.9% compared with the S&P 500 composite’s 11.9% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
QIAGEN N.V.’s (QGEN - Free Report) first-quarter 2025 adjusted earnings per share (EPS) were 55 cents, and 56 cents at constant exchange rate (CER). The bottom line increased 17% from the year-ago level. Additionally, it surpassed the Zacks Consensus Estimate by 10%.
The adjustment excludes the impact of certain non-recurring items, such as business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.
On a GAAP basis, EPS in the first quarter was 41 cents compared with 36 cents in the year-ago period.
Following the announcement, QGEN stock rose 1.1% yesterday.
QGEN’s Q1 Revenues
Net sales in the quarter were $483.5 million, up 5.4% from the year-ago figure (up 7% at CER). The top line beat the Zacks Consensus Estimate by 4.8%. (See the Zacks Earnings Calendar to stay ahead of market-making news.)
QGEN’s Q1 Revenue Breakdown
QIAGEN reports through product groups, namely Sample technologies, Diagnostic solutions, PCR / Nucleic acid amplification, Genomics / NGS and Other.
Sample technologies revenues plunged 3% on a reported basis (down 1% at CER) to $150 million. Our model projected $148 million for this segment.
Diagnostic solutions revenues rose 9% on a reported basis (11% at CER) to $187 million. Our model projected $183.7 million for this segment.
Within this, on a CER basis, QuantiFERON revenues were up 16% and QIAstat-Dx revenues surged 37%. Sales from NeuMoDx fell 36% at CER, while Other sales dropped 9% from the year-earlier level.
PCR/Nucleic acid amplification revenues increased 13% on a reported basis (up 14% at CER) to $76 million. Our model projected $66.6 million for this segment.
Genomics / NGS revenues totaled $53 million, down 3% year over year on a reported basis and 2% at CER. Our model projected $55 million for this segment.
Other revenues amounted to $18 million, up 57% year over year on a reported basis (up 64% at CER). Our model projected $10.7 million for this segment.
QIAGEN’s Operational Update
In the first quarter, the company’s cost of sales (excluding the amortization of acquisition-related intangibles) fell 6.3%. The adjusted gross profit rose 4.9% year over year to $322.2 million. Meanwhile, the adjusted gross margin contracted 29 basis points (bps) to 66.6%.
Sales and marketing expenses fell 4.3% year over year to $106.3 million. R&D expenses of $43.8 million were down 14.7% year over year. G&A expenses rose 14.6% year over year to $31.6 million.
Adjusted operating income (excluding items like acquisition-related intangible amortization, restructuring, integration and others) increased 20% year over year to $140.4 million. The adjusted operating margin expanded 354 bps to 29%.
QGEN’s Financial Update
QIAGEN exited the first quarter of 2025 with cash, cash equivalents and short-term investments of $963.4 million compared with $1.20 billion at the end of the fourth quarter of 2024.
QIAGEN N.V. Price, Consensus and EPS Surprise
QIAGEN N.V. price-consensus-eps-surprise-chart | QIAGEN N.V. Quote
The long-term debt (net of the current portion) was $1.35 billion at the end of the first quarter of 2025 compared with $1.34 billion at the end of the fourth quarter of 2024.
The net cash provided by operating activities at the end of the first quarter of 2025 was $139.7 million compared with $133.1 million in the year-ago period.
QIAGEN Reaffirms Outlook for 2025, Sets Q2 View
For 2025, net sales are expected to increase about 4% CER (about +5% CER core sales growth). The Zacks Consensus Estimate for revenues is pegged at $2.02 billion.
The adjusted EPS is expected to be $2.35 at CER (up from the previous outlook of $2.28 at CER). The Zacks Consensus Estimate is pegged at $2.27.
For the second quarter, the company estimates net sales to rise about 5% at CER (about 5% at CER in the core business) from $496 million in the prior-year period. The Zacks Consensus Estimate is currently pinned at $505.9 million.
The adjusted EPS is expected to be at least 60 cents at CER compared with 55 cents in the second quarter of 2024. The Zacks Consensus Estimate is pegged at 56 cents.
Our Take on QGEN
QIAGEN ended the first quarter of 2025 with better-than-expected results, wherein both earnings and revenues surpassed their respective estimates. The company’s performance reflect a resilient portfolio, with a substantial portion of sales coming from highly recurring revenues and a continued emphasis on delivering solid profitable growth in a challenging environment.
Diagnostic solutions registered the highest growth, driven by strong demand for QuantiFERON and QIAstat-Dx. PCR/Nucleic acid amplification technologies also posted solid growth, supported by the continued adoption of the QIAcuity digital PCR system. Consumables and related revenues grew while instrument sales were flat year over year, reflecting ongoing cautious capital spending trends among customers. Additionally, the expansion of operating margin in the quarter is encouraging.
QIAGEN remains focused on delivering on its 2025 outlook, paving the way for achieving its 2028 goal. However, rising costs and declining gross margins do not bode well.
QGEN’s Zacks Rank and Other Key Picks
QIAGEN currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks from the broader medical space are AngioDynamics (ANGO - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Boston Scientific (BSX - Free Report) .
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a loss of 13 cents. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 70.9%.
Integer Holdings, sporting a Zacks Rank #1 at present, posted a first-quarter 2025 adjusted EPS of $1.31, which outpaced the Zacks Consensus Estimate by 3.1%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%.
ITGR has an estimated long-term earnings growth rate of 20.8% compared with the industry’s 14.3%. The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 2.8%.
Boston Scientific, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 2.3%.
BSX has an estimated 2025 earnings growth rate of 15.9% compared with the S&P 500 composite’s 11.9% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.8%.